Reports Q4 revenue $148.7M, consensus $217.50M. Revenues from Naloxone products decreased 41% primarily due to increased competition, while Anthrax MCM products increased 64% due to the impact of timing. “Emergent’s 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage,” said CEO Joe Papa.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions announces up to C$140M in Canadian contracts
- Emergent BioSolutions authorizes $50M stock repurchase program
- Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Emergent BioSolutions gets FDA approval of sNDA for Narcan